Evaluation of the specificity of [18F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [18F]FDG and impact of rituximab therapy

9Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Background: [18F]Fludarabine is a novel positron emission tomography (PET) radiotracer for imaging lymphoma. The purpose of this preclinical study was to evaluate the robustness of [18F]fludarabine during rituximab therapy. In addition, a comparison was made between [18F]fludarabine and [18F]fluorodeoxyglucose ([18F]FDG) with regard to their concordance with histologically derived data.Methods: CB17-SCID mice bearing human follicular DOHH-2 lymphoma were treated once weekly with rituximab (10 mg/kg) or physiological saline over 3 weeks. To obtain the tracer uptake in the metabolically active volume of the tumour (MAVT), a background-level threshold was applied to the volume of interest (VOI) defined on computed tomography (CT) image. The tumour uptake analysis was performed with MAVT-based segmentation for data analysis of sequential [18F]fludarabine PET/CT studies and with total tumour-based segmentation for comparison with histologically derived data.Results: The correlation between the MAVT and [18F]fludarabine accumulation (%ID) in those viable tissues was equally significant for both vehicle- or rituximab-treated mice; for these latter, the presence of lymphoid tissues at the end of imaging sessions was confirmed histologically. A stronger correlation was demonstrated between quantitative values extracted from [18F]fludarabine-PET and histology (r2 = 0.91, p < 0.001) when compared to [18F]FDG-PET (r2 = 0.55, p = 0.03).Conclusions: [18F]Fludarabine uptake in the follicular lymphoma model compared favourably with [18F]FDG in terms of specificity for PET imaging and also remained robust for persistent viable tissues following rituximab therapy. [18F]Fludarabine PET/CT may be a promising approach to evaluate lymphoma, including their surveillance during therapy.

Cite

CITATION STYLE

APA

Hovhannisyan, N., Guillouet, S., Fillesoye, F., Dhilly, M., Patin, D., Galateau, F., … Barré, L. (2015). Evaluation of the specificity of [18F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [18F]FDG and impact of rituximab therapy. EJNMMI Research, 5(1). https://doi.org/10.1186/s13550-015-0101-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free